1. Feasibility of using phenylacetylpyridadiene, dwarf or salt derivatives with acceptable pharmacodynamics to reduce the number of multicellular cells to IL-6 and/or CD45 phenol in non-sclerosing cells.

摘要

A method of treating a subject presenting with multiple myeloma at a stage characterized by an increase in the prevalence of MM cells that (1) are IL-6 non-responsive and/or (2) have a CD45 phenotype, comprising administering to the subject an amount of a compound of formula Ib.